STRO stock news · Sutro Biopharma

Stories about Sutro Biopharma (STRO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for STRO

Follow Sutro Biopharma (STRO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 7, 2026, 9:54 AM ET · Market
Merck has stopped working on MK-1484, a drug it was developing with Sutro Biopharma.
Bad for STRO
Sutro loses a partnered drug program after Merck ended MK-1484 development. Merck called the choice routine, not a safety or efficacy response, but the canceled program is still a setback for Sutro.
Aug 12, 2026, 2:13 PM ET · Market
What factors are contributing to the decline of Sutro Biopharma's stock on Wednesday?
Bad for STRO
Sutro Biopharma's stock is down significantly following an update on its STRO-004 Phase 1 study, which revealed dose-limiting toxicity at higher doses and bearish technical indicators, leading to concerns about the stock's future performance.